Pfizer, Inc. · NYSE:PFE
Pfizer — Goldman Sachs 31st Annual Global Healthcare Conference (June 2010)
9 slides from Pfizer's conference presentation, Jun 15, 2010
Slide 1: Pfizer Inc. Specialty Care Business Review
Pfizer Inc. Specialty Care Business Review Geno Germano President & General Manager Specialty Care Business Unit Goldman-Sachs Healthcare Conference June 15, 2010
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this presentation will include forward- looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are di
Slide 3: SCBU Significantly Contributes to the Worldwide Biopharmaceutical Businesses
SCBU Significantly Contributes to the Worldwide Biopharmaceutical Businesses Strong portfolio of inline and pipeline assets More than 20 products spanning 11 disease areas Low near-term patent expiry exposure relative to the size of the overall business Significant and growing presence in Vacc
Slide 4: Pfizer is the Number One Specialty Care Company in the World
Pfizer is the Number One Specialty Care Company in the World Specialty Care’s Broad In-line Portfolio and Pipeline Span 11 Disease Areas Infectious Diseases PVD / PAH * Endocrine Ophthalmics Specialty Specialty Gastrointestinal Care Care BU BU Bapineuzumab / Neuroscience Hemophilia Disease Disease A
Slide 5: Prevenar 13 Platform: A Projected Growth Driver for Pfizer
Prevenar 13 Platform: A Projected Growth Driver for Pfizer Provides the broadest coverage of any pneumococcal conjugate vaccine Approved for pediatric use in over 50 countries Have entered into agreement with GAVI to improve access to Prevenar 13 in the developing world 5
Slide 6: Prevnar 13 Adult: Another Important Healthcare Opportunity
Prevnar 13 Adult: Another Important Healthcare Opportunity High Significant Excellent Incidence Unmet Need Profile IPD incidence in adults IPD and Pneumococcal Building on the >50 approaches Pneumonia are scientific foundation of incidence in children <5 associated with Prevnar mortality and signifi
Slide 7: Specialty Care Supports Other Key Development Initiatives Across Disease Areas
Pfizer Specialty Care Supports Other Key Development Initiatives Across Disease Areas Bapineuzumab * Tasocitinib Xiapex (Alzheimer’s (Inflammation) (Dupuytren’s) Disease) Novel MOA inhibiting Potential for disease Significant unmet the Jak Kinase modification in mild- need for less invasive inflamma
Slide 8: Specialty Care Provides Fertile Ground for Growth Organically and through BD
Pfizer Specialty Care Provides Fertile Ground for Growth Organically and through BD Strong Growth Potential in Key Disease Areas with Robust Substrate and Capabilities The Diverse Landscape Creates Opportunity to Excel in Many Different Areas Business Development viewed as an enabler of SCBU Strateg
Slide 9: Pfizer Inc. Specialty Care Business Review
Pfizer Inc. Specialty Care Business Review Geno Germano President & General Manager Specialty Care Business Unit Goldman-Sachs Healthcare Conference June 15, 2010
Pfizer — Goldman Sachs 31st Annual Global Healthcare Conference (June 2010) on 6ix